HanAll Biopharma

News

Immunovant shares were sliding today after it reported that FcRn blocker batoclimab failed a pair of phase 3 trials in thyroid eye disease.

News

Lundbeck has completed patient randomisation in a pivotal trial of epilepsy candidate bexicaserin, one of its major growth hopes.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.